Xeris Biopharma’s Beth Hecht sells $141,434 in company stock

Xeris Biopharma's Chief Legal Officer and Corporate Secretary, Beth Hecht, sold 16,666 shares of the company's common stock on September 1, 2026, generating $141,434. The shares were sold at prices ranging from $8.390 to $8.600, with a weighted average sale price of $8.4864. This sale occurred under a Rule 10b5-1 trading plan that Hecht established on August 8, 2025.

Despite the sale, Xeris shares have seen a 37.75% return over the past six months, though the stock is currently trading above its InvestingPro Fair Value, indicating potential overvaluation. Xeris Biopharma, valued at $1.54 billion, has impressive gross profit margins of 86.58%, even though it has not been profitable over the last twelve months.

The company reported a revenue of $92.1 million in the second quarter of 2026, a 29% increase from the previous year, driven by strong demand for RECORLEV and a rebound in sales of Gvoke. However, Xeris Biopharma posted a loss of $0.18 per share, missing analysts' expectations of a small profit of $0.01 per share due to a one-time non-cash GAAP charge related to convertible note remeasurement.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.